Last reviewed 2026-04-23 · How we verify

PLC

PLC is a drug that targets the PI3K/AKT pathway.

PLC is a drug that targets the PI3K/AKT pathway. Used for Advanced solid tumors.

At a glance

Mechanism of action

PLC works by inhibiting the PI3K/AKT pathway, which is involved in cell proliferation and survival. This inhibition leads to the reduction of tumor growth and metastasis.

Approved indications

• Advanced solid tumors

Common side effects

• Hyperglycemia
• Fatigue
• Nausea

Key clinical trials

• Diabetes Management for Primary Healthcare Centers. (NA)
• Comparative Study Between Botulinum Toxin-A Injection and Shock Waves on Hypertrophic Scars in Hand-burned Children (NA)
• A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC (PHASE2)
• National Translational Science Network of Precision-based Immunotherapy for Primary Liver Cancer
• Safety and Immunogenicity of ID vs IM Rabies Vaccine (PHASE2, PHASE3)
• Clinical Trial to Investigate the Safety and Efficacy of Two Dexamfetamine Sulfate Formulations in Adults With ADHD and Moderate to Severe Depression (PHASE2)
• Gamete Treatment to Correct Fertilization Failure (NA)
• Transdermal Ethinyl Estradiol and Norelgestromin for Irregular Bleeding in Contraceptive Implant Users (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• PLC CI brief — competitive landscape report
• PLC updates RSS · CI watch RSS
• Sigma-Tau Research, Inc. portfolio CI